How do you decide exactly where the treatment threshold should be?
Dr. Alex Kemper — lead author of the 2022 AAP Hyperbilirubinemia Guidelines — explains why determining phototherapy thresholds took years of debate, evidence review, and committee discussion.
With babies of different gestational ages, varying risk factors, and complex neurotoxicity considerations, there’s no single formula that solves it. Guideline writing meant balancing imperfect data, diverse perspectives, and the goal of protecting infants while avoiding unnecessary treatment.
This conversation is part of our series Rethinking Phototherapy.
→ Watch or listen to the full series on Apple Podcasts, Spotify, or at
the-incubator.org
.
If you’re passionate about thinking differently in neonatology and advancing innovation in our field, join us for Delphi this January in Florida. Learn more or register at
buff.ly/TsGL0X7
.
(Rethinking Phototherapy is made possible thanks to support from GE Healthcare.)